Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 47

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Sepsis+1

Not recruiting

Study on Epirubicin and Sodium Chloride for Patients with Sepsis or Septic Shock in Intensive Care Units

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Metastatic neoplasm+1

Not recruiting

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sorafenib
  • Sponsor:Medical Center - University Of Freiburg

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Study on the Safety and Effectiveness of Mebendazole and Low-Dose Cytarabine for Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Cytarabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Study on the Effectiveness of Human Hepatitis B Immunoglobulin for Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Hepatitis B Immunoglobulin
  • Sponsor:Medizinische Hochschule Hannover

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.